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Conclusion: Both SBRT and VMAT treatments were highly 
successful in terms of PSA control. QOL assessment were 
found to be mostly similar between treatment modalities. 
Grade 3 urinary toxicities might be eliminated with careful 
patient selection for SBRT technique 
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Purpose or Objective: The aim of this work is to develop an 
algorithm to predict recurrence in prostate cancer patients 
treated with radical radiotherapy, getting up to a prognostic 
power higher than traditional D'Amico risk classification.  
 
Material and Methods: 2493 men belonging to the EUREKA-2 
retrospective multi-centric database on prostate cancer and 
treated with external-beam radiotherapy (3D-CRT and or 
IMRT) as primary treatment comprised the study population. 
A Cox regression time to PSA failure analysis was performed 
in univariate and multivariate settings, evaluating the 
predictive ability of age, pre-treatment PSA, clinical-
radiological staging, Gleason score and percentage of positive 
cores at biopsy (%PC). The accuracy of this model was 
checked with bootstrapping statistics. Subgroups for all the 
variables' combinations were combined to classify patients 
into five different "Candiolo" risk-classes for biochemical 
Progression Free Survival (bPFS); thereafter, they were also 
applied to clinical PFS (cPFS), systemic PFS (sPFS) and 
Prostate Cancer Specific Survival (PCSS), and compared to 
D'Amico risk grouping performances.  
 
Results: the Candiolo classifier splits patients in 5 risk-groups 
with the following 10-years bPFS, cPFS, sPFS and PCSS: for 
very-low-risk 90%, 94%, 100% and 100%; for low-risk 74%, 88%, 
94% and 98%; for intermediate-risk 60%, 82%, 91% and 92%; 
for high-risk 43%, 55%, 80% and 89% and for very-high-risk 
14%, 38%, 56% and 70%. Our classifier outperforms D'Amico 
risk classes for all the end-points evaluated, with 
concordance indexes of 71.5%, 75.5%, 80% and 80.5% versus 
63%, 65.5%, 69.5% and 69%, respectively.  
 
Conclusion: Our classification tool, combining five clinical 
and easily available parameters, seems to better stratify 
patients in predicting prostate cancer recurrence after 
radiotherapy compared to the traditional D'Amico risk 
classes. This classifier must be validate by another prostate 
cancer series.  
References: Gabriele D et al: Beyond D'Amico risk classes for 
predicting recurrence after external beam radiotherapy for 
prostate cancer: the Candiolo classifier. Radiat Oncol 2015, 
in press 
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Purpose or Objective: To test the hypothesis that 
rectal/bladder preparation is associated with an increase in 
Cancer Specific Overall Survival (CSOS), in Clinical Disease 
Free (CDFS) and Biochemical Disease free Survival (BDFS) 
 
Material and Methods: From October 1999 to March 2012, 
1080 prostate cancer patients (PCa) were treated with 
3DCRT. 761 patients (pts) were treated with empty rectum 
and comfortable full bladder while for 319 pts no 
rectal/bladder preparation (NRBP) protocol was adopted. The 
mean age was 69.2±5.6 years. The mean prescribed dose was 
76±2 Gy. The mean followup was 81±39 months. Survival 
analysis was performed by Kaplan Meier method. Comparison 
between groups were made with the log–rank test. A Cox 
proportional hazards model was applied for univariate (UVA) 
and multivariate analysis (MVA). Hazard Ratio (HR) was used 
to measure how rapidly an event occurs. 
 
Results: Pts with rectal/bladder preparation (RBP) have 
significantly lower biochemical and clinical failures rates and 
lower risk of dying of PCa respect to NRBP pts (log-rank 
p<0.0001). At 140 months for RBP and NRPB, the CSOS was 
95% vs 85%, the CDFS was 81% vs 71%, the BDFS was 64% vs 48 
%, respectively. Table 1 shows UVA and MVA results. In MVA, 
for CSOS the Gleason Score (GS) and RBP predicted for death 
from PCa, while for CDSF and BDFS the GS, D’Amico Risk 
Classification, PSA, dose>75 Gy, clinical stage and RBP 
